{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:47:26Z","timestamp":1792000046983,"version":"4.4.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,17]]},"DOI":"10.7759\/cureus.60492","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T12:19:41Z","timestamp":1715948381000},"source":"Crossref","is-referenced-by-count":8,"title":["Prevalence, Attributes, and Risk Factors of QT-Interval-Prolonging Drugs and Potential Drug-Drug Interactions in Cancer Patients: A Prospective Study in a Tertiary Care Hospital"],"prefix":"10.7759","author":[{"given":"Akash","family":"Agnihotri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saravana Kumar","family":"Ramasubbu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkapal","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjunath","family":"Bidarolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uttam Kumar","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswadeep","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel RL","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024, 74:12-49. 10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2019.01.038","article-title":"Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease","volume":"280","author":"Totzeck M","year":"2019","unstructured":"Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol. 2019, 280:163-75. 10.1016\/j.ijcard.2019.01.038","journal-title":"Int J Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007724","article-title":"Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review","volume":"6","author":"Porta-S\u00e1nchez A","year":"2017","unstructured":"Porta-S\u00e1nchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, Thavendiranathan P. Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. J Am Heart Assoc. 2017, 6:007724. 10.1161\/JAHA.117.007724","journal-title":"J Am Heart Assoc"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-217158","article-title":"ECG changes in hyperemesis gravidarum","volume":"2017","author":"Mitchell SJ","year":"2017","unstructured":"Mitchell SJ, Cox P. ECG changes in hyperemesis gravidarum. BMJ Case Rep. 2017, 2017:bcr2016217158. 10.1136\/bcr-2016-217158","journal-title":"BMJ Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0406","article-title":"Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: a systematic review and meta-analysis","volume":"25","author":"Mohamed MR","year":"2020","unstructured":"Mohamed MR, Ramsdale E, Loh KP, et al.. Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: a systematic review and meta-analysis. Oncologist. 2020, 25:e94-e108. 10.1634\/theoncologist.2019-0406","journal-title":"Oncologist"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-017-0181-2","article-title":"Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study","volume":"18","author":"Khan Q","year":"2017","unstructured":"Khan Q, Ismail M, Khan S. Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study. BMC Pharmacol Toxicol. 2017, 18:75. 10.1186\/s40360-017-0181-2","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2019.03.008","article-title":"Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients","volume":"74","author":"Das B","year":"2019","unstructured":"Das B, Rawat VS, Ramasubbu SK, Kumar B. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients. Therapie. 2019, 74:599-609. 10.1016\/j.therap.2019.03.008","journal-title":"Therapie"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.11.009","article-title":"Management of QT prolongation induced by anti-cancer drugs: target therapy and old agents. Different algorithms for different drugs","volume":"63","author":"Coppola C","year":"2018","unstructured":"Coppola C, Rienzo A, Piscopo G, Barbieri A, Arra C, Maurea N. Management of QT prolongation induced by anti-cancer drugs: target therapy and old agents. Different algorithms for different drugs. Cancer Treat Rev. 2018, 63:135-43. 10.1016\/j.ctrv.2017.11.009","journal-title":"Cancer Treat Rev"},{"key":"ref9","unstructured":"QT Drugs Lists, AzCERT, Drugs to be Avoided by Congenital Long QT Patients. (2023). Accessed. January 02, 2024: http:\/\/www.CredibleMeds.org."},{"key":"ref10","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. ATC\/DDD Index. (2023). Accessed. January 02, 2024: https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/atc-classification."},{"key":"ref11","unstructured":"Drug Interactions Checker. (2023). Accessed. January 02, 2024: https:\/\/www.drugs.com\/drug_interactions.html."},{"key":"ref12","unstructured":"Epocrates Online Interaction Check. (2023). Accessed. January 02, 2024: https:\/\/online.epocrates.com\/interaction-check."},{"key":"ref13","unstructured":"Drug Interaction Checker. (2023). Accessed. January 02, 2024: https:\/\/reference.medscape.com\/drug-interactionchecker."},{"key":"ref14","unstructured":"Lexicomp Drug Interactions-UpToDate. (2023). Accessed. January 02. (2023). https:\/\/www.uptodate.com\/drug-interactions\/?source=responsive_home#di-druglist."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2165\/11536840-000000000-00000","article-title":"Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands","volume":"33","author":"van Noord C","year":"2010","unstructured":"van Noord C, Dieleman JP, van Herpen G, Verhamme K, Sturkenboom MC. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf. 2010, 33:1003-14. 10.2165\/11536840-000000000-00000","journal-title":"Drug Saf"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2016","article-title":"Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study","volume":"19","author":"Johannes CB","year":"2010","unstructured":"Johannes CB, Varas-Lorenzo C, McQuay LJ, Midkiff KD, Fife D. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010, 19:881-8. 10.1002\/pds.2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e31827afd0d","article-title":"Domperidone: limited benefits with significant risk for sudden cardiac death","volume":"61","author":"Hondeghem LM","year":"2013","unstructured":"Hondeghem LM. Domperidone: limited benefits with significant risk for sudden cardiac death. J Cardiovasc Pharmacol. 2013, 61:218-25. 10.1097\/FJC.0b013e31827afd0d","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0360-0","article-title":"Domperidone and risk of ventricular arrhythmia and cardiac death: a systematic review and meta-analysis","volume":"36","author":"Leelakanok N","year":"2016","unstructured":"Leelakanok N, Holcombe A, Schweizer ML. Domperidone and risk of ventricular arrhythmia and cardiac death: a systematic review and meta-analysis. Clin Drug Investig. 2016, 36:97-107. 10.1007\/s40261-015-0360-0","journal-title":"Clin Drug Investig"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi312","article-title":"Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death","volume":"26","author":"Straus SM","year":"2005","unstructured":"Straus SM, Sturkenboom MC, Bleumink GS, et al.. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005, 26:2007-12. 10.1093\/eurheartj\/ehi312","journal-title":"Eur Heart J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.14503\/THIJ-16-6040","article-title":"Torsades de pointes after ondansetron infusion in 2 patients","volume":"44","author":"Lee DY","year":"2017","unstructured":"Lee DY, Trinh T, Roy SK. Torsades de pointes after ondansetron infusion in 2 patients. Tex Heart Inst J. 2017, 44:366-9. 10.14503\/THIJ-16-6040","journal-title":"Tex Heart Inst J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp161070","article-title":"Effect of a single dose of i.v. ondansetron on QTc interval in emergency department patients","volume":"75","author":"Li K","year":"2018","unstructured":"Li K, Vo K, Lee BK, Addo N, Coralic Z. Effect of a single dose of i.v. ondansetron on QTc interval in emergency department patients. Am J Health Syst Pharm. 2018, 75:276-82. 10.2146\/ajhp161070","journal-title":"Am J Health Syst Pharm"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2013.10.026","article-title":"Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis","volume":"64","author":"Freedman SB","year":"2014","unstructured":"Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med. 2014, 64:19-25.e6. 10.1016\/j.annemergmed.2013.10.026","journal-title":"Ann Emerg Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2016.08.058","article-title":"Risk of ventricular arrhythmias and association with ondansetron","volume":"179","author":"Moeller JR","year":"2016","unstructured":"Moeller JR, Gummin DD, Nelson TJ, Drendel AL, Shah BK, Berger S. Risk of ventricular arrhythmias and association with ondansetron. J Pediatr. 2016, 179:118-123.e1. 10.1016\/j.jpeds.2016.08.058","journal-title":"J Pediatr"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jelectrocard.2008.07.016","article-title":"T(p-e)\/QT ratio as an index of arrhythmogenesis","volume":"41","author":"Gupta P","year":"2008","unstructured":"Gupta P, Patel C, Patel H, Narayanaswamy S, Malhotra B, Green JT, Yan GX. T(p-e)\/QT ratio as an index of arrhythmogenesis. J Electrocardiol. 2008, 41:567-74. 10.1016\/j.jelectrocard.2008.07.016","journal-title":"J Electrocardiol"},{"key":"ref25","article-title":"Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels","volume":"295","author":"Kuryshev YA","year":"2000","unstructured":"Kuryshev YA, Brown AM, Wang L, Benedict CR, Rampe D. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther. 2000, 295:614-20.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2023.04.003","article-title":"QT prolongation, torsades des pointes, and cardiac arrest after 4 mg of IV ondansetron","volume":"68","author":"Orozco BS","year":"2023","unstructured":"Orozco BS, Lee SC, Fuchs RT, Fushianes GD, Cole JB. QT prolongation, torsades des pointes, and cardiac arrest after 4 mg of IV ondansetron. Am J Emerg Med. 2023, 68:214.e3-6. 10.1016\/j.ajem.2023.04.003","journal-title":"Am J Emerg Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S25623","article-title":"Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study","volume":"3","author":"Hafermann MJ","year":"2011","unstructured":"Hafermann MJ, Namdar R, Seibold GE, Page RL 2nd. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthc Patient Saf. 2011, 3:53-8. 10.2147\/DHPS.S25623","journal-title":"Drug Healthc Patient Saf"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/acem.12836","article-title":"Intravenous ondansetron and the QT interval in adult emergency department patients: an observational study","volume":"23","author":"Moffett PM","year":"2016","unstructured":"Moffett PM, Cartwright L, Grossart EA, O'Keefe D, Kang CS. Intravenous ondansetron and the QT interval in adult emergency department patients: an observational study. Acad Emerg Med. 2016, 23:102-5. 10.1111\/acem.12836","journal-title":"Acad Emerg Med"},{"key":"ref29","unstructured":"FDA Drug Safety Communication. Abnormal Heart Rhythms May Be Associated With Use of Zofran (Ondansetron). (2023271913). Accessed: January 27, 2024: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm271913.htm."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79380-1","article-title":"Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QT(C) interval in patients with malignancy: a prospective, observational, single-group, assessor-blinded study","volume":"11","author":"Kamath A","year":"2021","unstructured":"Kamath A, Rai KM, Shreyas R, Saxena PU, Banerjee S. Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QT(C) interval in patients with malignancy: a prospective, observational, single-group, assessor-blinded study. Sci Rep. 2021, 11:445. 10.1038\/s41598-020-79380-1","journal-title":"Sci Rep"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-019-00949-6","article-title":"Drug-drug interactions in patients undergoing chemoradiotherapy and the impact of an expert team intervention","volume":"42","author":"Daggupati SJ","year":"2020","unstructured":"Daggupati SJ, Saxena PU, Kamath A, Chowta MN. Drug-drug interactions in patients undergoing chemoradiotherapy and the impact of an expert team intervention. Int J Clin Pharm. 2020, 42:132-40. 10.1007\/s11096-019-00949-6","journal-title":"Int J Clin Pharm"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2014.899406","article-title":"Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism in vitro","volume":"44","author":"Youssef AS","year":"2014","unstructured":"Youssef AS, Parkman HP, Nagar S. Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism in vitro. Xenobiotica. 2014, 44:792-803. 10.3109\/00498254.2014.899406","journal-title":"Xenobiotica"},{"key":"ref33","article-title":"Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans","volume":"23","author":"Dixon C","year":"1995","unstructured":"Dixon C, Colthup P, Serabjit-Singh CJ, Kerr BM, Boehlert CC, Park GR, Tarbit MH. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos. 1995, 23:1225-30.","journal-title":"Drug Metab Dispos"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70130-X","article-title":"The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron","volume":"65","author":"Villikka K","year":"1999","unstructured":"Villikka K, Kivisto K, Neuvonen P. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clin Pharmacol Ther. 1999, 65:377-81. 10.1016\/S0009-9236(99)70130-X","journal-title":"Clin Pharmacol Ther"},{"key":"ref35","article-title":"The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron","volume":"22","author":"Fischer V","year":"1994","unstructured":"Fischer V, Vickers A, Heitz F, Mahadevan S, Baldeck JP, Minery P, Tynes R. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos. 1994, 22:269-74.","journal-title":"Drug Metab Dispos"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e31821d01bc","article-title":"CYP2D6- and CYP3A-dependent enantioselective plasma concentrations of ondansetron in postanesthesia care","volume":"113","author":"Stamer UM","year":"2011","unstructured":"Stamer UM, Lee EH, Rauers NI, et al.. CYP2D6- and CYP3A-dependent enantioselective plasma concentrations of ondansetron in postanesthesia care. Anesth Analg. 2011, 113:48-54. 10.1213\/ANE.0b013e31821d01bc","journal-title":"Anesth Analg"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12614","article-title":"Drug-drug interactions in pharmacologic management of gastroparesis","volume":"27","author":"Youssef AS","year":"2015","unstructured":"Youssef AS, Parkman HP, Nagar S. Drug-drug interactions in pharmacologic management of gastroparesis. Neurogastroenterol Motil. 2015, 27:1528-41. 10.1111\/nmo.12614","journal-title":"Neurogastroenterol Motil"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/647476","article-title":"Risk of mortality (including sudden cardiac death) and major cardiovascular events in users of olanzapine and other antipsychotics: a study with the general practice research database","volume":"2013","author":"Jones ME","year":"2013","unstructured":"Jones ME, Campbell G, Patel D, et al.. Risk of mortality (including sudden cardiac death) and major cardiovascular events in users of olanzapine and other antipsychotics: a study with the general practice research database. Cardiovasc Psychiatry Neurol. 2013, 2013:647476. 10.1155\/2013\/647476","journal-title":"Cardiovasc Psychiatry Neurol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15810","article-title":"Navigating the minefield of QTc interval-prolonging therapy in nursing facility residents","volume":"67","author":"Zarowitz BJ","year":"2019","unstructured":"Zarowitz BJ, Tisdale JE. Navigating the minefield of QTc interval-prolonging therapy in nursing facility residents. J Am Geriatr Soc. 2019, 67:1508-15. 10.1111\/jgs.15810","journal-title":"J Am Geriatr Soc"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S287042","article-title":"Effects of antipsychotics on arrhythmogenic parameters in schizophrenia patients: beyond corrected QT interval","volume":"17","author":"Okayasu H","year":"2021","unstructured":"Okayasu H, Shinozaki T, Takano Y, et al.. Effects of antipsychotics on arrhythmogenic parameters in schizophrenia patients: beyond corrected QT interval. Neuropsychiatr Dis Treat. 2021, 17:239-49. 10.2147\/NDT.S287042","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1080\/15360288.2021.1900491","article-title":"The risk of QTc prolongation with antiemetics in the palliative care setting: a narrative review","volume":"35","author":"Gavioli EM","year":"2021","unstructured":"Gavioli EM, Guardado N, Haniff F, Deiab N, Vider E. The risk of QTc prolongation with antiemetics in the palliative care setting: a narrative review. J Pain Palliat Care Pharmacother. 2021, 35:125-35. 10.1080\/15360288.2021.1900491","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1218","article-title":"Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia","volume":"26","author":"Suzuki Y","year":"2011","unstructured":"Suzuki Y, Ono S, Sugai T, et al.. Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia. Hum Psychopharmacol. 2011, 26:440-3. 10.1002\/hup.1218","journal-title":"Hum Psychopharmacol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.44.2.174","article-title":"QTc prolongation and high-dose olanzapine","volume":"44","author":"Dineen S","year":"2003","unstructured":"Dineen S, Withrow K, Voronovitch L, Munshi F, Nawbary MW, Lippmann S. QTc prolongation and high-dose olanzapine. Psychosomatics. 2003, 44:174-5. 10.1176\/appi.psy.44.2.174","journal-title":"Psychosomatics"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2013.862258","article-title":"Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care","volume":"52","author":"Petersen AB","year":"2014","unstructured":"Petersen AB, Andersen SE, Christensen M, Larsen HL. Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care. Clin Toxicol (Phila). 2014, 52:39-43. 10.3109\/15563650.2013.862258","journal-title":"Clin Toxicol (Phila)"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.2174\/1574886311666160225150405","article-title":"Tramadol induced QTc-interval prolongation: prevalence, clinical factors and correlation to plasma concentrations","volume":"11","author":"Keller GA","year":"2016","unstructured":"Keller GA, Etchegoyen MC, Fernandez N, et al.. Tramadol induced QTc-interval prolongation: prevalence, clinical factors and correlation to plasma concentrations. Curr Drug Saf. 2016, 11:206-14. 10.2174\/1574886311666160225150405","journal-title":"Curr Drug Saf"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1159\/000492616","article-title":"Opioids and cardiac arrhythmia: a literature review","volume":"27","author":"Behzadi M","year":"2018","unstructured":"Behzadi M, Joukar S, Beik A. Opioids and cardiac arrhythmia: a literature review. Med Princ Pract. 2018, 27:401-14. 10.1159\/000492616","journal-title":"Med Princ Pract"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.473","article-title":"Tramadol hydrochloride at steady state lacks clinically relevant QTc interval increases in healthy adults","volume":"8","author":"Massarella J","year":"2019","unstructured":"Massarella J, Ariyawansa J, Natarajan J, et al.. Tramadol hydrochloride at steady state lacks clinically relevant QTc interval increases in healthy adults. Clin Pharmacol Drug Dev. 2019, 8:95-106. 10.1002\/cpdd.473","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2020-0026","article-title":"Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics","volume":"21","author":"Saiz-Rodr\u00edguez M","year":"2020","unstructured":"Saiz-Rodr\u00edguez M, Ochoa D, Rom\u00e1n M, Zubiaur P, Koller D, Mej\u00eda G, Abad-Santos F. Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics. Pharmacogenomics. 2020, 21:663-75. 10.2217\/pgs-2020-0026","journal-title":"Pharmacogenomics"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200105000-00045","article-title":"The analgesic efficacy of tramadol is impaired by concurrent administration of ondansetron","volume":"92","author":"De Witte JL","year":"2001","unstructured":"De Witte JL, Schoenmaekers B, Sessler DI, Deloof T. The analgesic efficacy of tramadol is impaired by concurrent administration of ondansetron. Anesth Analg. 2001, 92:1319-21. 10.1097\/00000539-200105000-00045","journal-title":"Anesth Analg"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200206000-00033","article-title":"Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT(3) spinal receptor involvement in acute pain in humans","volume":"94","author":"Arcioni R","year":"2002","unstructured":"Arcioni R, della Rocca M, Roman\u00f2 S, Romano R, Pietropaoli P, Gasparetto A. Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT(3) spinal receptor involvement in acute pain in humans. Anesth Analg. 2002, 94:1553-7, table of contents. 10.1097\/00000539-200206000-00033","journal-title":"Anesth Analg"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: a review","volume":"10","author":"Sara JD","year":"2018","unstructured":"Sara JD, Kaur J, Khodadadi R, et al.. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018, 10:1758835918780140. 10.1177\/1758835918780140","journal-title":"Ther Adv Med Oncol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1159\/000331645","article-title":"Clinical and electrocardiography changes in patients treated with capecitabine","volume":"57","author":"Koca D","year":"2011","unstructured":"Koca D, Salman T, Unek IT, Oztop I, Ellidokuz H, Eren M, Yilmaz U. Clinical and electrocardiography changes in patients treated with capecitabine. Chemotherapy. 2011, 57:381-7. 10.1159\/000331645","journal-title":"Chemotherapy"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jccase.2017.03.009","article-title":"A case of ventricular fibrillation as a consequence of capecitabine-induced secondary QT prolongation: a case report","volume":"16","author":"Hayasaka K","year":"2017","unstructured":"Hayasaka K, Takigawa M, Takahashi A, et al.. A case of ventricular fibrillation as a consequence of capecitabine-induced secondary QT prolongation: a case report. J Cardiol Cases. 2017, 16:26-9. 10.1016\/j.jccase.2017.03.009","journal-title":"J Cardiol Cases"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1080\/00015385.2021.1873548","article-title":"5-Fluorouracil, capecitabine and vasospasm: a scoping review of pathogenesis, management options and future research considerations","volume":"77","author":"Teperikidis E","year":"2022","unstructured":"Teperikidis E, Boulmpou A, Charalampidis P, Tsavousoglou C, Giannakoulas G, Papadopoulos CE, Vassilikos V. 5-Fluorouracil, capecitabine and vasospasm: a scoping review of pathogenesis, management options and future research considerations. Acta Cardiol. 2022, 77:1-13. 10.1080\/00015385.2021.1873548","journal-title":"Acta Cardiol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab035","article-title":"Cardiotoxicity from capecitabine chemotherapy: prospective study of incidence at rest and during physical exercise","volume":"27","author":"Lestuzzi C","year":"2022","unstructured":"Lestuzzi C, Stolfo D, De Paoli A, et al.. Cardiotoxicity from capecitabine chemotherapy: prospective study of incidence at rest and during physical exercise. Oncologist. 2022, 27:e158-67. 10.1093\/oncolo\/oyab035","journal-title":"Oncologist"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-017-9416-0","article-title":"Additive proarrhythmic effect of combined treatment with QT-prolonging agents","volume":"18","author":"Frommeyer G","year":"2018","unstructured":"Frommeyer G, Fischer C, Ellermann C, et al.. Additive proarrhythmic effect of combined treatment with QT-prolonging agents. Cardiovasc Toxicol. 2018, 18:84-90. 10.1007\/s12012-017-9416-0","journal-title":"Cardiovasc Toxicol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2008.05.013","article-title":"Effect of domperidone on QT interval in neonates","volume":"153","author":"Djeddi D","year":"2008","unstructured":"Djeddi D, Kongolo G, Lefaix C, Mounard J, L\u00e9k\u00e9 A. Effect of domperidone on QT interval in neonates. J Pediatr. 2008, 153:663-6. 10.1016\/j.jpeds.2008.05.013","journal-title":"J Pediatr"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-004-0922-z","article-title":"QT interval prolongation associated with the oral use of domperidone in an infant","volume":"26","author":"Rocha CM","year":"2005","unstructured":"Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol. 2005, 26:720-3. 10.1007\/s00246-004-0922-z","journal-title":"Pediatr Cardiol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e31827e2573","article-title":"Domperidone and sudden cardiac death: how much longer should we wait?","volume":"61","author":"Michaud V","year":"2013","unstructured":"Michaud V, Turgeon J. Domperidone and sudden cardiac death: how much longer should we wait?. J Cardiovasc Pharmacol. 2013, 61:215-7. 10.1097\/FJC.0b013e31827e2573","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.20.1468.34482","article-title":"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin","volume":"21","author":"Frothingham R","year":"2001","unstructured":"Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy. 2001, 21:1468-72. 10.1592\/phco.21.20.1468.34482","journal-title":"Pharmacotherapy"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.2165\/11531850-000000000-00000","article-title":"Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System","volume":"33","author":"Poluzzi E","year":"2010","unstructured":"Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf. 2010, 33:303-14. 10.2165\/11531850-000000000-00000","journal-title":"Drug Saf"},{"key":"ref62","article-title":"A case of ofloxacin-induced torsades de pointes and abnormal ECG change mimicking acute myocardial infarction","volume":"32","author":"Kim JH","year":"2002","unstructured":"Kim JH, Nam GB, Lim JM, et al.. A case of ofloxacin-induced torsades de pointes and abnormal ECG change mimicking acute myocardial infarction. Korean Circ J. 2002, 32:815-9.","journal-title":"Korean Circ J"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.11.011","article-title":"Arrhythmias associated with fluoroquinolone therapy","volume":"29","author":"Falagas ME","year":"2007","unstructured":"Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents. 2007, 29:374-9. 10.1016\/j.ijantimicag.2006.11.011","journal-title":"Int J Antimicrob Agents"},{"key":"ref64","article-title":"Levofloxacin-induced torsades de pointes","volume":"37","author":"Patel PD","year":"2010","unstructured":"Patel PD, Afshar H, Birnbaum Y. Levofloxacin-induced torsades de pointes. Tex Heart Inst J. 2010, 37:216-7.","journal-title":"Tex Heart Inst J"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8159.2003.00367.x","article-title":"Quinolones: cardioprotective or cardiotoxic","volume":"26","author":"Katritsis D","year":"2003","unstructured":"Katritsis D, Camm AJ. Quinolones: cardioprotective or cardiotoxic. Pacing Clin Electrophysiol. 2003, 26:2317-20. 10.1111\/j.1540-8159.2003.00367.x","journal-title":"Pacing Clin Electrophysiol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1080\/02841860802199816","article-title":"Oxaliplatin-induced long QT syndrome in a patient with appendiceal adenocarcinoma","volume":"48","author":"Woei Chung L","year":"2009","unstructured":"Woei Chung L, Liao YM, Hsieh CY, Lin CY. Oxaliplatin-induced long QT syndrome in a patient with appendiceal adenocarcinoma. Acta Oncol. 2009, 48:156-7. 10.1080\/02841860802199816","journal-title":"Acta Oncol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2012.762999","article-title":"Oxaliplatin-induced torsades de pointes and long QT syndrome in a patient with gastric cancer","volume":"52","author":"Kim HJ","year":"2013","unstructured":"Kim HJ, An SH, Cho YH, Kim SY, Lee HG, Yoon SY. Oxaliplatin-induced torsades de pointes and long QT syndrome in a patient with gastric cancer. Acta Oncol. 2013, 52:1223-4. 10.3109\/0284186X.2012.762999","journal-title":"Acta Oncol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcma.2013.05.001","article-title":"Oxaliplatin-induced acquired long QT syndrome with torsades de pointes and myocardial injury in a patient with dilated cardiomyopathy and rectal cancer","volume":"76","author":"Chang RY","year":"2013","unstructured":"Chang RY, Lee MY, Kan CB, Hsu WP, Hsiao PC. Oxaliplatin-induced acquired long QT syndrome with torsades de pointes and myocardial injury in a patient with dilated cardiomyopathy and rectal cancer. J Chin Med Assoc. 2013, 76:466-9. 10.1016\/j.jcma.2013.05.001","journal-title":"J Chin Med Assoc"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1177\/2042098616666081","article-title":"QT interval prolongation and torsades de pointes with oxaliplatin","volume":"7","author":"Hancox JC","year":"2016","unstructured":"Hancox JC, Caves RE, Choisy SC, James AF. QT interval prolongation and torsades de pointes with oxaliplatin. Ther Adv Drug Saf. 2016, 7:261-3. 10.1177\/2042098616666081","journal-title":"Ther Adv Drug Saf"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25008","article-title":"Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives","volume":"9","author":"Duan J","year":"2018","unstructured":"Duan J, Tao J, Zhai M, et al.. Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives. Oncotarget. 2018, 9:25738-49. 10.18632\/oncotarget.25008","journal-title":"Oncotarget"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-6576.2002.460725.x","article-title":"Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest","volume":"46","author":"Bentsen G","year":"2002","unstructured":"Bentsen G, Stubhaug A. Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest. Acta Anaesthesiol Scand. 2002, 46:908-10. 10.1034\/j.1399-6576.2002.460725.x","journal-title":"Acta Anaesthesiol Scand"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1007\/BF03021028","article-title":"Asystolic cardiac arrest: an unusual reaction following iv metoclopramide","volume":"50","author":"Grenier Y","year":"2003","unstructured":"Grenier Y, Drolet P. Asystolic cardiac arrest: an unusual reaction following iv metoclopramide. Can J Anaesth. 2003, 50:333-5. 10.1007\/BF03021028","journal-title":"Can J Anaesth"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(94)90978-4","article-title":"Total heart block after intravenous metoclopramide","volume":"343","author":"Midttun M","year":"1994","unstructured":"Midttun M, Bjarne O. Total heart block after intravenous metoclopramide. Lancet. 1994, 343:182-3. 10.1016\/s0140-6736(94)90978-4","journal-title":"Lancet"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-7-200904070-00016","article-title":"Metoclopramide as a possible cause of prolonged QT syndrome and torsade de pointes in a patient with heart failure and renal insufficiency","volume":"150","author":"Siddique SM","year":"2009","unstructured":"Siddique SM, Shariff N, Vesuwala N, Hafiz T. Metoclopramide as a possible cause of prolonged QT syndrome and torsade de pointes in a patient with heart failure and renal insufficiency. Ann Intern Med. 2009, 150:502-4. 10.7326\/0003-4819-150-7-200904070-00016","journal-title":"Ann Intern Med"},{"key":"ref75","article-title":"Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block","volume":"24","author":"Chou CC","year":"2001","unstructured":"Chou CC, Wu D. Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block. Chang Gung Med J. 2001, 24:805-9.","journal-title":"Chang Gung Med J"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-198801000-00021","article-title":"Supraventricular tachycardia associated with postpartum metoclopramide administration","volume":"68","author":"Bevacqua BK","year":"1988","unstructured":"Bevacqua BK. Supraventricular tachycardia associated with postpartum metoclopramide administration. Anesthesiology. 1988, 68:124-5. 10.1097\/00000542-198801000-00021","journal-title":"Anesthesiology"},{"key":"ref77","article-title":"Circulatory collapse in a patient with gastrinoma after metoclopramide administration","volume":"15","author":"Lau KK","year":"2009","unstructured":"Lau KK, Chan KW, Lok CM, et al.. Circulatory collapse in a patient with gastrinoma after metoclopramide administration. Hong Kong Med J. 2009, 15:478-81.","journal-title":"Hong Kong Med J"},{"key":"ref78","article-title":"Torsades de pointes induced by metoclopramide injection","volume":"49","author":"Susanto DH","year":"2018","unstructured":"Susanto DH, Budiono B. Torsades de pointes induced by metoclopramide injection. Medicina. 2018, 49:331-5.","journal-title":"Medicina"},{"key":"ref79","article-title":"Cardiovascular adverse effects of metoclopramide: review of literature","volume":"3","author":"Rumore MM","year":"2012","unstructured":"Rumore MM. Cardiovascular adverse effects of metoclopramide: review of literature. Int J Case Rep Imag. 2012, 3:1-10.","journal-title":"Int J Case Rep Imag"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1159\/000083234","article-title":"Comparison of the effects of metoclopramide and domperidone on HERG channels","volume":"74","author":"Claassen S","year":"2005","unstructured":"Claassen S, Z\u00fcnkler BJ. Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005, 74:31-6. 10.1159\/000083234","journal-title":"Pharmacology"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1001\/archfami.1.2.271","article-title":"Metoclopramide-associated tardive dyskinesia. An analysis of 67 cases","volume":"1","author":"Sewell DD","year":"1992","unstructured":"Sewell DD, Jeste DV. Metoclopramide-associated tardive dyskinesia. An analysis of 67 cases. Arch Fam Med. 1992, 1:271-8. 10.1001\/archfami.1.2.271","journal-title":"Arch Fam Med"},{"key":"ref82","article-title":"The effects of ondansetron and metoclopramide used for postoperative nausea and vomiting prophylaxis on the QT interval","volume":"25","author":"Bilgin S","year":"2008","unstructured":"Bilgin S, Eksi A, Sener EB. The effects of ondansetron and metoclopramide used for postoperative nausea and vomiting prophylaxis on the QT interval. Ondokuz Mayis Universities Tip Dergisi. 2008, 25:117-24.","journal-title":"Ondokuz Mayis Universities Tip Dergisi"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3182522624","article-title":"Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters","volume":"46","author":"Parkman HP","year":"2012","unstructured":"Parkman HP, Mishra A, Jacobs M, Pathikonda M, Sachdeva P, Gaughan J, Krynetskiy E. Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters. J Clin Gastroenterol. 2012, 46:494-503. 10.1097\/MCG.0b013e3182522624","journal-title":"J Clin Gastroenterol"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2019.1645594","article-title":"Metoclopramide for the treatment of diabetic gastroparesis","volume":"13","author":"Shakhatreh M","year":"2019","unstructured":"Shakhatreh M, Jehangir A, Malik Z, Parkman HP. Metoclopramide for the treatment of diabetic gastroparesis. Expert Rev Gastroenterol Hepatol. 2019, 13:711-21. 10.1080\/17474124.2019.1645594","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.2217\/fon.10.74","article-title":"Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer","volume":"6","author":"Navari RM","year":"2010","unstructured":"Navari RM. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol. 2010, 6:1073-84. 10.2217\/fon.10.74","journal-title":"Future Oncol"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.2174\/1574884713666180223123947","article-title":"Drug-induced QT interval prolongation in the intensive care unit","volume":"12","author":"Etchegoyen CV","year":"2017","unstructured":"Etchegoyen CV, Keller GA, Mrad S, Cheng S, Di Girolamo G. Drug-induced QT interval prolongation in the intensive care unit. Curr Clin Pharmacol. 2017, 12:210-22. 10.2174\/1574884713666180223123947","journal-title":"Curr Clin Pharmacol"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.4097\/kjae.2013.65.5.397","article-title":"Intravenous palonosetron increases the incidence of QTc prolongation during sevoflurane general anesthesia for laparotomy","volume":"65","author":"Min JJ","year":"2013","unstructured":"Min JJ, Yoo Y, Kim TK, Lee JM. Intravenous palonosetron increases the incidence of QTc prolongation during sevoflurane general anesthesia for laparotomy. Korean J Anesthesiol. 2013, 65:397-402. 10.4097\/kjae.2013.65.5.397","journal-title":"Korean J Anesthesiol"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6349(07)70675-4","article-title":"High dose palonosetron does not alter ECG parameters including QTC interval in healthy subjects: results of a dose-response, double blind, randomized, parallel E14 study of palonosetron versus moxifloxacin or placebo","volume":"5","author":"Morganroth J","year":"2007","unstructured":"Morganroth J, Parisi S, Moresino C, Thorn M, Cullen MT. High dose palonosetron does not alter ECG parameters including QTC interval in healthy subjects: results of a dose-response, double blind, randomized, parallel E14 study of palonosetron versus moxifloxacin or placebo. Eur J Cancer. 2007, 5:158-9. 10.1016\/S1359-6349(07)70675-4","journal-title":"Eur J Cancer"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2822-6","article-title":"Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers","volume":"24","author":"Morganroth J","year":"2016","unstructured":"Morganroth J, Flaharty KK, Parisi S, Moresino C. Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers. Support Care Cancer. 2016, 24:621-7. 10.1007\/s00520-015-2822-6","journal-title":"Support Care Cancer"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225040-00004","article-title":"Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview","volume":"25","author":"De Ponti F","year":"2002","unstructured":"De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf. 2002, 25:263-86. 10.2165\/00002018-200225040-00004","journal-title":"Drug Saf"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(87)90824-1","article-title":"QT prolongation and torsades de pointes after administration of trimethoprim-sulfamethoxazole","volume":"59","author":"Lopez JA","year":"1987","unstructured":"Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T. QT prolongation and torsades de pointes after administration of trimethoprim-sulfamethoxazole. Am J Cardiol. 1987, 59:376-7. 10.1016\/0002-9149(87)90824-1","journal-title":"Am J Cardiol"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-992147","article-title":"Torsade de pointes during combined treatment with risperidone and citalopram","volume":"40","author":"Blaschke D","year":"2007","unstructured":"Blaschke D, Parwani AS, Huemer M, Rolf S, Boldt LH, Dietz R, Haverkamp W. Torsade de pointes during combined treatment with risperidone and citalopram. Pharmacopsychiatry. 2007, 40:294-5. 10.1055\/s-2007-992147","journal-title":"Pharmacopsychiatry"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2016.03.047","article-title":"Loperamide abuse associated with cardiac dysrhythmia and death","volume":"69","author":"Eggleston W","year":"2017","unstructured":"Eggleston W, Clark KH, Marraffa JM. Loperamide abuse associated with cardiac dysrhythmia and death. Ann Emerg Med. 2017, 69:83-6. 10.1016\/j.annemergmed.2016.03.047","journal-title":"Ann Emerg Med"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5040176","article-title":"Loperamide induced life threatening ventricular arrhythmia","volume":"2016","author":"Upadhyay A","year":"2016","unstructured":"Upadhyay A, Bodar V, Malekzadegan M, Singh S, Frumkin W, Mangla A, Doshi K. Loperamide induced life threatening ventricular arrhythmia. Case Rep Cardiol. 2016, 2016:5040176. 10.1155\/2016\/5040176","journal-title":"Case Rep Cardiol"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4061980","article-title":"Loperamide induced torsades de pointes: a case report and review of the literature","volume":"2016","author":"Mukarram O","year":"2016","unstructured":"Mukarram O, Hindi Y, Catalasan G, Ward J. Loperamide induced torsades de pointes: a case report and review of the literature. Case Rep Med. 2016, 2016:4061980. 10.1155\/2016\/4061980","journal-title":"Case Rep Med"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2016.1159310","article-title":"Not your regular high: cardiac dysrhythmias caused by loperamide","volume":"54","author":"Wightman RS","year":"2016","unstructured":"Wightman RS, Hoffman RS, Howland MA, Rice B, Biary R, Lugassy D. Not your regular high: cardiac dysrhythmias caused by loperamide. Clin Toxicol (Phila). 2016, 54:454-8. 10.3109\/15563650.2016.1159310","journal-title":"Clin Toxicol (Phila)"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytz150","article-title":"Loperamide overdose causing torsades de pointes and requiring Impella temporary mechanical support: a case report","volume":"3","author":"Cicci JD","year":"2019","unstructured":"Cicci JD, Jagielski SM, Clarke MM, Rayson RA, Cavender MA. Loperamide overdose causing torsades de pointes and requiring Impella temporary mechanical support: a case report. Eur Heart J Case Rep. 2019, 3:1-6. 10.1093\/ehjcr\/ytz150","journal-title":"Eur Heart J Case Rep"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2016.12.079","article-title":"Loperamide misuse and abuse","volume":"57","author":"Miller H","year":"2017","unstructured":"Miller H, Panahi L, Tapia D, Tran A, Bowman JD. Loperamide misuse and abuse. J Am Pharm Assoc (2003). 2017, 57:S45-50. 10.1016\/j.japh.2016.12.079","journal-title":"J Am Pharm Assoc (2003)"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1080\/21548331.2018.1530831","article-title":"Cardiotoxicity of cancer chemotherapy in clinical practice","volume":"47","author":"Jain D","year":"2019","unstructured":"Jain D, Aronow W. Cardiotoxicity of cancer chemotherapy in clinical practice. Hosp Pract (1995). 2019, 47:6-15. 10.1080\/21548331.2018.1530831","journal-title":"Hosp Pract (1995)"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi JJ","year":"2016","unstructured":"Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016, 375:1457-67. 10.1056\/NEJMra1100265","journal-title":"N Engl J Med"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab362","article-title":"Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study","volume":"42","author":"Salem JE","year":"2021","unstructured":"Salem JE, Nguyen LS, Moslehi JJ, et al.. Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. Eur Heart J. 2021, 42:3915-28. 10.1093\/eurheartj\/ehab362","journal-title":"Eur Heart J"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2022.2037139","article-title":"The prevalence of polypharmacy and potential drug-drug interactions among Iranian cancer patients: which patients were at risk?","volume":"40","author":"Bazrafshani MS","year":"2022","unstructured":"Bazrafshani MS, Pardakhty A, Kalantari Khandani B, et al.. The prevalence of polypharmacy and potential drug-drug interactions among Iranian cancer patients: which patients were at risk?. Cancer Invest. 2022, 40:457-72. 10.1080\/07357907.2022.2037139","journal-title":"Cancer Invest"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03783-9","article-title":"Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer","volume":"83","author":"Hoemme A","year":"2019","unstructured":"Hoemme A, Barth H, Haschke M, et al.. Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer. Cancer Chemother Pharmacol. 2019, 83:763-74. 10.1007\/s00280-019-03783-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-019-00910-7","article-title":"Prevalence of potential drug-drug interactions in outpatients on treatment with parenteral antineoplastic drugs","volume":"41","author":"Castro-Manzanares M","year":"2019","unstructured":"Castro-Manzanares M, do Pazo-Oubi\u00f1a F, Rodr\u00edguez-Rinc\u00f3n RM. Prevalence of potential drug-drug interactions in outpatients on treatment with parenteral antineoplastic drugs. Int J Clin Pharm. 2019, 41:1429-33. 10.1007\/s11096-019-00910-7","journal-title":"Int J Clin Pharm"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-10839-6_1","article-title":"Polypharmacy in Cancer Therapy","author":"Lima Cavalcanti ID","year":"2022","unstructured":"Lima Cavalcanti ID. Polypharmacy in Cancer Therapy. Chemotherapy Protocols and Infusion Sequence. Springer, Cham; 2022. 1-25. 10.1007\/978-3-031-10839-6_1"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33324","article-title":"Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer","volume":"127","author":"Lee RT","year":"2021","unstructured":"Lee RT, Kwon N, Wu J, et al.. Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer. Cancer. 2021, 127:1827-35. 10.1002\/cncr.33324","journal-title":"Cancer"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03625-3","article-title":"Interactions in cancer treatment considering cancer therapy, concomitant medications, food, herbal medicine and other supplements","volume":"148","author":"Wolf CP","year":"2022","unstructured":"Wolf CP, Rachow T, Ernst T, et al.. Interactions in cancer treatment considering cancer therapy, concomitant medications, food, herbal medicine and other supplements. J Cancer Res Clin Oncol. 2022, 148:461-73. 10.1007\/s00432-021-03625-3","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02809.x","article-title":"Comparative assessment of four drug interaction compendia","volume":"63","author":"Vitry AI","year":"2007","unstructured":"Vitry AI. Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol. 2007, 63:709-14. 10.1111\/j.1365-2125.2006.02809.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0359-4","article-title":"Recognition and management of potential drug-drug interactions in patients on internal medicine wards","volume":"63","author":"Vonbach P","year":"2007","unstructured":"Vonbach P, Dubied A, Beer JH, Kr\u00e4henb\u00fchl S. Recognition and management of potential drug-drug interactions in patients on internal medicine wards. Eur J Clin Pharmacol. 2007, 63:1075-83. 10.1007\/s00228-007-0359-4","journal-title":"Eur J Clin Pharmacol"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/j.explore.2010.06.004","article-title":"Evidence-based management of herb-drug interaction in cancer chemotherapy","volume":"6","author":"Cheng CW","year":"2010","unstructured":"Cheng CW, Fan W, Ko SG, Song L, Bian ZX. Evidence-based management of herb-drug interaction in cancer chemotherapy. Explore (NY). 2010, 6:324-9. 10.1016\/j.explore.2010.06.004","journal-title":"Explore (NY)"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1786-7","article-title":"Drug-drug interaction software in clinical practice: a systematic review","volume":"71","author":"Roblek T","year":"2015","unstructured":"Roblek T, Vaupotic T, Mrhar A, Lainscak M. Drug-drug interaction software in clinical practice: a systematic review. Eur J Clin Pharmacol. 2015, 71:131-42. 10.1007\/s00228-014-1786-7","journal-title":"Eur J Clin Pharmacol"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1159\/000351133","article-title":"Potential interactions with anticancer agents: a cross-sectional study","volume":"59","author":"Mouzon A","year":"2013","unstructured":"Mouzon A, Kerger J, D'Hondt L, Spinewine A. Potential interactions with anticancer agents: a cross-sectional study. Chemotherapy. 2013, 59:85-92. 10.1159\/000351133","journal-title":"Chemotherapy"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2018-314674","article-title":"Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs","volume":"105","author":"Pezo RC","year":"2019","unstructured":"Pezo RC, Yan AT, Earle C, Chan KK. Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs. Heart. 2019, 105:1649-55. 10.1136\/heartjnl-2018-314674","journal-title":"Heart"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-020-0221-y","article-title":"An overview of clinical decision support systems: benefits, risks, and strategies for success","volume":"3","author":"Sutton RT","year":"2020","unstructured":"Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An overview of clinical decision support systems: benefits, risks, and strategies for success. NPJ Digit Med. 2020, 3:17. 10.1038\/s41746-020-0221-y","journal-title":"NPJ Digit Med"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2021.04.006","article-title":"Machine learning in clinical decision making","volume":"2","author":"Adlung L","year":"2021","unstructured":"Adlung L, Cohen Y, Mor U, Elinav E. Machine learning in clinical decision making. Med. 2021, 2:642-65. 10.1016\/j.medj.2021.04.006","journal-title":"Med"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2020-107102","article-title":"Machine learning in medicine: should the pursuit of enhanced interpretability be abandoned?","volume":"48","author":"Yoon CH","year":"2022","unstructured":"Yoon CH, Torrance R, Scheinerman N. Machine learning in medicine: should the pursuit of enhanced interpretability be abandoned?. J Med Ethics. 2022, 48:581-5. 10.1136\/medethics-2020-107102","journal-title":"J Med Ethics"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/243750-prevalence-attributes-and-risk-factors-of-qt-interval-prolonging-drugs-and-potential-drug-drug-interactions-in-cancer-patients-a-prospective-study-in-a-tertiary-care-hospital","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T12:19:52Z","timestamp":1715948392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/243750-prevalence-attributes-and-risk-factors-of-qt-interval-prolonging-drugs-and-potential-drug-drug-interactions-in-cancer-patients-a-prospective-study-in-a-tertiary-care-hospital"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":116,"URL":"https:\/\/doi.org\/10.7759\/cureus.60492","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,17]]}}}